secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2021-11-17T23:59:59+00:00
Accession:  0000950170-21-004713
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta appoints Stephen Mayo to board, promotes Rodino-Klapac to R&D head, O'Neill departs
--------------------------------------------------------------------------------

- Stephen L. Mayo appointed to Sarepta board, effective Nov 16, 2021; receives $712,500 equity grant split between RSUs and options plus $50k annual cash.
- Louise Rodino-Klapac promoted to Head of R&D, Chief Scientific Officer; granted 40,000 RSUs vesting 25% annually over 4 years.
- Gilmore O'Neill mutually agreed to end employment effective Nov 30, 2021; will serve as consultant through Q1 2022.
- Outstanding equity awards issued to O'Neill continue to vest during the consulting period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/srpt-20211115.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer